Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial
-
Published:2024
Issue:
Volume:40
Page:100817
-
ISSN:2468-2942
-
Container-title:Cancer Treatment and Research Communications
-
language:en
-
Short-container-title:Cancer Treatment and Research Communications
Author:
Kaidarova Dilyara,
Zhavrid Edvard,
Shatkovskaya Oxana,
Prokharau Aliaksandr,
Akhmed Nina,
Sembayev Dauren,
Rutzhanova Zhanna,
Ivankov AlexandrORCID
Funder
F Hoffmann-La Roche Ltd
Reference22 articles.
1. Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics;Anderson;Future Oncol.,2019
2. Trastuzumab in breast cancer;Emens;Oncology,2004
3. Fagg J. Herceptin biosimilars – the real prize remains Europe. 2014. Available from: https://www.evaluate.com/vantage/articles/news/herceptin-biosimilars-real-prize-remains-europe.
4. Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients;Farolfi;Oncotarget,2017
5. Herceptin [package insert],2018